Repligen Corporation (RGEN) Reached 52-Week High at $47.72

June 29, 2018 - By Ira Colvard

Repligen Corporation (NASDAQ:RGEN) Corporate Logo

Big Money Sentiment increased to 1.39 in Q1 2018. It has change of 0.13, from 2017Q4’s 1.26. The ratio is positive due to Repligen Corporation positioning: 13 sold and 46 reduced. 19 funds amassed stakes and 63 increased stakes. Investors holded 35.19 million in 2017Q4 but now own 35.98 million shares or 2.25% more.
Legal General Gp Public Limited Co reported 77,094 shs stake. Pnc Fincl Services Inc invested in 0% or 58,830 shs. 3,600 were reported by Numerixs Invest Tech Inc. Piedmont Invest Advsr Limited Liability has invested 0.01% of its capital in Repligen Corporation (NASDAQ:RGEN). First Mercantile Company has 2,960 shs for 0.02% of their capital. California Employees Retirement owns 125,214 shs or 0.01% of their US capital. Credit Suisse Ag holds 40,643 shs. Ny State Teachers Retirement Systems stated it has 52,686 shs. Mackenzie Fincl has 946,366 shs. Nuveen Asset Ltd holds 0.01% in Repligen Corporation (NASDAQ:RGEN) or 21,246 shs. Dekabank Deutsche Girozentrale holds 0% or 17,600 shs. Ameriprise Fincl, Minnesota-based fund reported 776,567 shs. Wells Fargo Com Mn invested in 0.01% or 738,506 shs. South Dakota Invest Council invested in 0.05% or 58,700 shs. Lord Abbett & Limited Liability Co stated it has 196,083 shs or 0.02% of all its holdings.

Repligen Corporation had 8 sales and 0 insider purchases since January 22, 2018. This’s net activity of $13.05 million. Shares for $85,606 were sold by RYAN THOMAS F JR on Wednesday, June 6. Shares for $5.00M were sold by EDDLEMAN ROY T on Wednesday, May 16. On Friday, May 11 $835,936 worth of Repligen Corporation (NASDAQ:RGEN) was sold by DAWES KAREN A. On Wednesday, May 9 BARTHELEMY NICOLAS also sold $1.07M worth of Repligen Corporation (NASDAQ:RGEN).

Repligen Corporation (NASDAQ:RGEN) hit $47.72 stock price also a yearly high. It was published on Jun, 29 according to Barchart.com. It has $2.09 billion MC. The valuation of NASDAQ:RGEN can change by $145.95M if our $51.06 price target is hit.

The stock increased 1.97% or $0.92 during the last trading session, touching $47.72.Repligen Corporation has volume of 118,185 shares. Since June 29, 2017 RGEN has risen 11.84% and is uptrending. RGEN underperformed the S&P 500 by 0.73%.

Earnings report for Repligen Corporation (NASDAQ:RGEN) is expected on August, 2., RTT reports. Analysts expect change of 5.00 % or $0.01 from previous year’s $0.2 EPS compared to current’s $0.19 EPS. In case of $0.19 EPS RGEN’s profit could hit $8.30M. Wall Street now forecasts 11.76 % EPS growth despite Repligen Corporation last quarter’s EPS of $0.17.

A couple more Repligen Corporation (NASDAQ:RGEN) news were published by: Nasdaq.com which released on June 28, 2018 “Repligen Selects Purolite Life Sciences as Commercial Partner for New High Performance Ligand”, also Nasdaq.com on June 27, 2018 published “Repligen Announces Agreement with Navigo Proteins for the Exclusive Co-Development of Next Generation Affinity …”, the next Benzinga.com is “Benzinga’s Daily Biotech Pulse: Pain Therapeutics Drops 70%, Neon To Begin Trading” on June 27, 2018. Globenewswire.com has article titled “Report: Exploring Fundamental Drivers Behind Matthews International, Raytheon, JetBlue Airways, Repligen, Becton …”.

Repligen Corporation, a bioprocessing company, focuses on the development, production, and commercialization of products used in the production of antibody therapeutics, recombinant proteins, and vaccines worldwide.The firm is worth $2.09 billion. It makes various forms of Protein A, a critical component used to purify antibody drugs.66.28 is the P/E ratio. The firm also supplies alternating tangential flow system filtration devices and protein cell culture supplements that are used in clinical and commercial stage manufacturing to enhance biologic drug yields.

Repligen Corporation (NASDAQ:RGEN) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.